Results 31 to 40 of about 16,388 (147)

Proprotein convertase subtilisin/Kexin type-9 (PCSK-9) inhibitors induced liver injury - a retrospective analysis

Journal of Community Hospital Internal Medicine Perspectives, 2020
Background Proprotein convertase subtilisin/Kexin type 9 (PCSK-9) inhibitors induced liver dysfunction in patients with or without previous liver injury, and this is not well discussed in the previous literature.
Yousuf Zafar, Yasar Sattar, Waqas Ullah, Sohaib Roomi, Mamoon-Ur- Rashid, Muhammad Shayan Khan, Laura Schmidt   +6 more
doaj   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

PCSK9 E670G Polymorphism and Its Clinical Implications in Obese Elderly Patients Undergoing Bariatric Surgery

Proceedings
Introduction: The PCSK9 gene encodes the NARC-1 protein, a key regulator of cholesterol metabolism [...]
Dante M. T. Teixeira, Calliandra M. S. Silva, Matheus G. Castro, Gustavo M. Ferreira, Juliana M. A. Seixas, Caroline F. Fratelli, Rosana C. Benito, Evelyn M. Kogawa, Linconl A. O. Benito, Izabel C. R. Silva   +9 more
doaj   +1 more source

Coming Back to Physiology: Extra Hepatic Functions of Proprotein Convertase Subtilisin/Kexin Type 9

Frontiers in Physiology, 2020
Neuronal apoptosis regulated convertase-1 (NARC-1), now mostly known as proprotein convertase subtilisin/kexin type 9 (PCSK9), has received a lot of attention due to the fact that it is a key regulator of the low-density lipoprotein (LDL) receptor (LDL-R)
Klaus-Dieter Schlüter, Annemarie Wolf, Rolf Schreckenberg   +2 more
doaj   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Targeting PCSK9 in Vascular Smooth Muscle Cells: An Effective Strategy to Suppress Ferroptosis and Attenuate Abdominal Aortic Aneurysm Progression

Cell Proliferation, EarlyView.
PCSK9 aggravates AAA by promoting ferroptosis in VSMCs. In the pathological AAA environment, PCSK9 upregulation triggers ferritinophagy‐dependent degradation of FTH1, leading to Fe2+ release, triggering lipid peroxidation and ferroptosis, exacerbating AAA.
Mengdie Xia, Man Li, Yanyu Chen, Jialin Chen, Yuting Cui, Xi‐Long Zheng, Jing Yang, Bingzhao Li, Xiaofeng Ma, Miao Liu, Gang Fan, Juan Peng, Xiaoyan Dai, Zhihan Tang   +13 more
wiley   +1 more source

Comparative Effects of Emerging Lp(a)‐Lowering Agents and PCSK9‐Directed Therapies on Lipoprotein(a): A Network Meta‐Analysis of Randomised Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Elevated lipoprotein(a) [Lp(a)] is a genetic ASCVD risk factor that often persists despite intensive LDL‐C lowering. We compared the efficacy and safety of emerging Lp(a)‐targeted therapies (siRNAs, antisense oligonucleotides and an oral assembly inhibitor) with PCSK9‐directed therapies.
Jihad Abu Zayed, Nada A. Al‐Awamleh, Mahmoud Hamad, Mohammad Ibrahim Mahmoud Hdaib, Hazem Ayesh   +4 more
wiley   +1 more source

Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels

Journal of Lipid Research, 2010
Over the past several years, proprotein convertase subtilisin kexin type 9 (PCSK9) has gained significant attention as a key regulator of serum LDL-cholesterol (LDL-C) levels.
Jason S. Troutt, William E. Alborn, Guoqing Cao, Robert J. Konrad   +3 more
doaj   +1 more source

An update on the landscape of collagen bioactive fragments

The FEBS Journal, EarlyView.
The remodeling of the extracellular matrix releases collagen bioactive fragments, which exert molecular functions and regulate numerous biological processes via several signaling pathways. Here, we summarize the latest findings describing the roles of major bioactive fragments from collagens I, IV, VI, and XVIII in various physiological and ...
Sylvie Ricard‐Blum, Julie Fradette
wiley   +1 more source

Proteolysis at the extracellular matrix interface: Molecular architects and regulators in health and disease

The FEBS Journal, EarlyView.
The extracellular matrix (ECM) is a dynamic scaffold that orchestrates tissue architecture and cellular communication. A critical but underexplored interplay between proteases and cluster of differentiation molecules (CD) governs ECM turnover and directs cell fate.
David Jurnečka, Matija Hrovatin, Bor Bokalj, Boris Turk   +3 more
wiley   +1 more source